Table 4. Overview of most discriminating metabolites, their treatment effect and their metabolite response in the OGTT time course.

	Metabolite	Treatment effect (%): Diclofenac vs placebo
		Mean	Range		Response type
GC-MS	Uric acid	−12	−18	1	A
	1,2-diglyceride (C36:2)	−18	−28	−9	A
	Proline	9	6	13	A
	Isoleucine	−18	−22	−13	A
	1-aminocyclopentanecarboxylic acid	−2	−5	2	A
	Threonine	−13	−15	−11	A
	4-Hydroxyproline	−59	−72	−51	A
	2,3,4-Trihydroxybutanoic acid	15	9	24	A
	Aminoadipic acid	−26	−43	−16	A
	Arabitol, ribitol, or xylitol	10	5	13	A
	Ornithine	−12	−20	2	A
	Mannose or galactose	10	6	14	A
	Palmitoleic acid (C16:1)	23	−2	55	A
	Palmitic acid (C16:0)	6	−13	24	A
LC-MS	Isoleucine	−23	−34	−15	A
	Glycine	8			B
	2-Amino-2-methyl butanoic acid	−4	−9	−1	A
	5-Oxoproline	14			B
	1-Aminocyclopentanecarboxylic acid	−69	−91	−35	A
	4-Hydroxyproline	−52	−61	−38	A
	Isoleucine & Leucine (not resolved)	−8	−13	−1	A
	Hippuric acid	63	48	75	A
	5-Oxoproline (acetonitrile adduct)	8			B
	Aspartic acid	9			B
	Glutamic acid	4			B
	Citric acid	−10	−18	6	A

Per analytical platform the metabolites are ranked according to their importance to the model, thus uric acid and isoleucine contributed most in the discrimination between the treatment groups.

Only identified metabolites are shown in Table 4. The column ‘response type’ refers to Figure 2; metabolites with response type A showed a treatment difference over the whole time course and metabolites with response type B showed a treatment difference only in the second part of the time course (a response of the metabolite in the placebo group, whereas no change in the diclofenac treated group). For metabolites with response type B the mean is calculated over the time points with a treatment difference.